The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential
Open accessAbstract
The transcription factor nuclear factor erythroid 2‐related factor 2 (NRF2) is considered the master regulator of the phase II antioxidant response. It controls a plethora of cytoprotective genes related to oxidative stress, inflammation, and protein homeostasis, among other processes. Activation of these pathways has been described in numerous pathologies including cancer, cardiovascular, respiratory, renal, digestive, metabolic, autoimmune, and neurodegenerative diseases. Considering the increasing interest of discovering novel NRF2 activators due to its clinical application, initial efforts were devoted to the development of electrophilic drugs able to induce NRF2 nuclear accumulation by targeting its natural repressor protein Kelch‐like ECH‐associated protein 1 (KEAP1) through covalent modifications on cysteine residues. However, off‐target effects of these drugs prompted the development of an innovative strategy, the search of KEAP1‐NRF2 protein–protein interaction (PPI) inhibitors. These innovative activators are proposed to target NRF2 in a more selective way, leading to potentially improved drugs with the application for a variety of diseases that are currently under investigation. In this review, we summarize known KEAP1‐NRF2 PPI inhibitors to date and the bases of their design highlighting the most important features of their respective interactions. We also discuss the preclinical pharmacological properties described for the most promising compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903
Reactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Sies, H., Berndt, C., & Jones, D. P. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045037 · Cited by 3,520
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
ZINC: A Free Tool to Discover Chemistry for Biology
Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., & Coleman, R. G. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3001277 · Cited by 2,509
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova-Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,141
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878 · cited 1×
“, interleukin [IL]‐6 and IL‐1β) due to NRF2 binding to the proximity of these genes.(28)”
BackgroundNRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672
Moi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607
Zhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480 · cited 1×
“, Cys151 at the BTB domain, Cys226, Cys273, and Cys288 at the IVR domain, and Cys613 at the Kelch domain) that act as cellular redox status sensors.(37,38) The relationship of these Cys residues with the activation of the NRF2 pathway has been detailed in the so‐called “Hinge and latch model.”
BackgroundTherapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Self-citationDissecting molecular cross-talk between Nrf2 and NF-κB response pathways
Wardyn, J. D., Ponsford, A. H., & Sanderson, C. M. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150014 · Cited by 1,200 · cited 2×
“Complementarily, there is a competition between NRF2 and NF‐κB‐p65 subunit to bind the transcriptional co‐activator CBP (CREB‐binding protein)–p300 complex, which enhances gene transcription by direct NRF2 or p65 acetylation and potentiates the activation of the antioxidant response or the pro‐inflammatory pathway, re…”
Background(2002) · PubMed · Cited by 1,190
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Sheedy, F. J., Grebe, A., Rayner, K. J., Kalantari, P., Ramkhelawon, B., Carpenter, S. B., Becker, C. E., Ediriweera, H. N., Mullick, A. E., Golenbock, D. T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2639 · Cited by 935
Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation
Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D. R., et al. (2003) · Nature Genetics · doi:10.1038/ng1248 · Cited by 883
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759 · cited 7×
“There are only KEAP1 binding data and crystallographic information, but there is a lack of competition experiments with NRF2.”
BackgroundInfluentialStructural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 2×
“NRF2‐ETGE‐motif‐containing peptides cocrystallized with KEAP1‐Kelch domain adopt a β‐hairpin conformation within the binding site that comprises residues Asp77, Glu78, Glu79, Thr80, Gly81, and Glu82.(59,61) This conformation is stabilized by an intramolecular hydrogen bonds network involving backbone atoms of residues”
BackgroundLiu, G.-H., Qu, J., & Shen, X. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.002 · Cited by 697 · cited 1×
“Complementarily, there is a competition between NRF2 and NF‐κB‐p65 subunit to bind the transcriptional co‐activator CBP (CREB‐binding protein)–p300 complex, which enhances gene transcription by direct NRF2 or p65 acetylation and potentiates the activation of the antioxidant response or the pro‐inflammatory pathway, re…”
BackgroundBuendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., & León, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 678
Self-citationChowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., & Hayes, J. D. (2013) · Oncogene · doi:10.1038/onc.2012.388 · Cited by 657
Self-citationMcMahon, M. J., Itoh, K., Yamamoto, M. P., Chanas, S. A., Henderson, C. J., McLellan, L. I., Wolf, C. R., Cavin, C., & Hayes, J. D. (2001) · PubMed · Cited by 651
An open-source drug discovery platform enables ultra-large virtual screens
Gorgulla, C., Boeszoermenyi, A., Wang, Z.-F., Fischer, P. D., Coote, P. W., Padmanabha Das, K. M., Malets, Y. S., Radchenko, D. S., Moroz, Y. S., Scott, D. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2117-z · Cited by 641
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
Self-citationSingh, A., Venkannagari, S., Oh, K. H., Zhang, Y.-Q., Rohde, J. M., Liu, L., Nimmagadda, S., Sudini, K., Brimacombe, K. R., Gajghate, S., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00651 · Cited by 617
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
Lo, S., Li, X., Henzl, M. T., Beamer, L. J., & Hannink, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601243 · Cited by 604 · cited 3×
“NRF2‐ETGE‐motif‐containing peptides cocrystallized with KEAP1‐Kelch domain adopt a β‐hairpin conformation within the binding site that comprises residues Asp77, Glu78, Glu79, Thr80, Gly81, and Glu82.(59,61) This conformation is stabilized by an intramolecular hydrogen bonds network involving backbone atoms of residues”
BackgroundKwak, M.-K., Itoh, K., Yamamoto, M., & Kensler, T. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.9.2883-2892.2002 · Cited by 593
Structural basis of Keap1 interactions with Nrf2
Canning, P., Sorrell, F. J., & Bullock, A. N. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.034 · Cited by 592
Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism
Tong, K. I., Kobayashi, A., Katsuoka, F., & Yamamoto, M. (2006) · Biological Chemistry · doi:10.1515/bc.2006.164 · Cited by 473 · cited 1×
“Thus, the DLG motif could act as a latch to either enable or disable NRF2 degradation, depending on the redox state (Figure 1).(39,40) In this line, some classical electrophilic NRF2 inducers are known to modify Cys residues at KEAP1, that is, 1‐[2‐ cyano‐3,12‐dioxooleana‐1,9(11)‐dien‐28‐oyl] imidazole (CDDO‐Im) and s…”
BackgroundTong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-07 · Cited by 442
Sun, Z., Chin, Y. E., & Zhang, D. D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01639-08 · Cited by 414
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M., & Hayes, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403061200 · Cited by 404
Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes
Pajares, M., Jiménez-Moreno, N., García-Yagüe, Á. J., Escoll, M., de Ceballos, M. L., Van Leuven, F., Rábano, A., Yamamoto, M., Rojo, A. I., & Cuadrado, A. (2016) · Autophagy · doi:10.1080/15548627.2016.1208889 · Cited by 392
Self-citationSaito, T., Ichimura, Y., Taguchi, K., Suzuki, T., Mizushima, T., Takagi, K., Hirose, Y., Nagahashi, M., Iso, T., Fukutomi, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12030 · Cited by 362
Selective autophagy as a potential therapeutic target for neurodegenerative disorders
Scrivo, A., Bourdenx, M., Pampliega, O., & Cuervo, A. M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30238-2 · Cited by 355
Davies, T. G., Wixted, W. E., Coyle, J. E., Griffiths-Jones, C., Hearn, K., McMenamin, R., Norton, D., Rich, S. J., Richardson, C., Saxty, G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00228 · Cited by 322
MacLeod, A. K., McMahon, M., Plummer, S. M., Higgins, L. G., Penning, T. M., Igarashi, K., & Hayes, J. D. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp176 · Cited by 297
Modulating protein–protein interactions: the potential of peptides
Nevola, L., & Giralt, E. (2015) · Chemical Communications · doi:10.1039/c4cc08565e · Cited by 289
Smith, M. C., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 286
Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease
Aleksunes, L. M., & Manautou, J. E. (2007) · Toxicologic Pathology · doi:10.1080/01926230701311344 · Cited by 285
Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases
Canning, P., Cooper, C. D. O., Krojer, T., Murray, J. W., Pike, A. C. W., Chaikuad, A., Keates, T., Thangaratnarajah, C., Hojzan, V., Marsden, B. D., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.437996 · Cited by 284 · cited 1×
“To date, the KEAP1 and NRF2 full‐length structures have not been described, although a complete structural model of the CRL complex can be assembled from its different crystallized subunits (Figure 2A).(36,58) Nevertheless, KEAP1‐ Kelch domain complexed with NRF2 peptides containing the ETGE or DLG motifs have been re…”
BackgroundBeyond repression of Nrf2: An update on Keap1
Kopacz, A., Kloska, D., Forman, H. J., Jozkowicz, A., & Grochot-Przeczek, A. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.03.023 · Cited by 265
Fukutomi, T., Takagi, K., Mizushima, T., Ohuchi, N., & Yamamoto, M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01191-13 · Cited by 260
Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
Cleasby, A., Yon, J., Day, P. J., Richardson, C., Tickle, I. J., Williams, P. A., Callahan, J. F., Carr, R., Concha, N., Kerns, J. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098896 · Cited by 258
Jiang, Z.-Y., Lu, M.-C., Xu, L., Yang, T.-T., Xi, M.-Y., Xu, X.-L., Guo, X.-K., Zhang, X.-J., You, Q.-D., & Sun, H.-P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000529 · Cited by 252
Marcotte, D., Zeng, W., Hus, J.-C., McKenzie, A., Hession, C., Jin, P., Bergeron, C., Lugovskoy, A., Enyedy, I., Cuervo, H., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.019 · Cited by 239
Nrf2 Expression Is Regulated by Epigenetic Mechanisms in Prostate Cancer of TRAMP Mice
Yu, S., Khor, T. O., Cheung, K.-L., Li, W., Wu, T.-Y., Huang, Y., Foster, B. A., Kan, Y. W., & Kong, A.-N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008579 · Cited by 228
Kim, J.-E., You, D.-J., Lee, C., Ahn, C., Seong, J. Y., & Hwang, J.-I. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.06.004 · Cited by 222
Pajares, M., Rojo, A. I., Arias, E., Díaz-Carretero, A., Cuervo, A. M., & Cuadrado, A. (2018) · Autophagy · doi:10.1080/15548627.2018.1474992 · Cited by 218
Self-citationRachakonda, G., Xiong, Y., Sekhar, K. R., Stamer, S. L., Liebler, D. C., & Freeman, M. L. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700302s · Cited by 207
Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction
Hu, L., Magesh, S., Chen, L., Wang, L., Lewis, T. A., Chen, Y., Khodier, C., Inoyama, D., Beamer, L. J., Emge, T. J., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.013 · Cited by 200
Molecular basis for the disruption of Keap1–Nrf2 interaction via Hinge & Latch mechanism
Horie, Y., Suzuki, T., Inoue, J., Iso, T., Wells, G., Moore, T. W., Mizushima, T., Dinkova-Kostova, A. T., Kasai, T., Kamei, T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02100-6 · Cited by 189
Brennan, M. S., Matos, M. F., Li, B., Hronowski, X., Gao, B., Juhasz, P., Rhodes, K. J., & Scannevin, R. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120254 · Cited by 188 · cited 1×
“The DMF‐derived metabolite, monomethyl fumarate (MMF), readily reacts with Cys151 at the BTB domain of KEAP1 to induce NRF2 pathway activation.(49,50) Important examples of electrophilic NRF2 induces are sulforaphane and cyanoenone triterpenoids, that are also under clinical evaluation.”
BackgroundPeptides and peptidomimetics as regulators of protein–protein interactions
Cunningham, A. D., Qvit, N., & Mochly-Rosen, D. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.12.009 · Cited by 185
Binding Mode and Structure–Activity Relationships around Direct Inhibitors of the Nrf2–Keap1 Complex
Jnoff, E., Albrecht, C., Barker, J. J., Barker, O., Beaumont, E., Bromidge, S., Brookfield, F., Brooks, M., Bubert, C., Ceska, T., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300525 · Cited by 176
Eggler, A. L., Small, E., Hannink, M., & Mesecar, A. D. (2009) · Biochemical Journal · doi:10.1042/bj20090471 · Cited by 176
DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner
Gillard, G. O., Collette, B., Anderson, J., Chao, J., Scannevin, R. H., Huss, D. J., & Fontenot, J. D. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.006 · Cited by 173
Kaidery, N. A., Banerjee, R., Yang, L., Smirnova, N. A., Hushpulian, D. M., Liby, K. T., Williams, C. R., Yamamoto, M., Kensler, T. W., Ratan, R. R., et al. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4491 · Cited by 170
Regulation of the Keap1–Nrf2 pathway by p62/SQSTM1
Katsuragi, Y., Ichimura, Y., & Komatsu, M. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.09.005 · Cited by 168
Monitoring Keap1–Nrf2 interactions in single live cells
Baird, L., Swift, S., Llères, D., & Dinkova-Kostova, A. T. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.03.004 · Cited by 167
PMI: A ΔΨm Independent Pharmacological Regulator of Mitophagy
East, D. A., Fagiani, F., Crosby, J., Georgakopoulos, N., Bertrand, H. C., Schaap, M., Fowkes, A., Wells, G., & Campanella, M. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.019 · Cited by 161
Zhuang, C., Narayanapillai, S. C., Zhang, W., Sham, Y. Y., & Xing, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017174 · Cited by 159
Lu, M., Zhao, J., Liu, Y.-T., Liu, T., Tao, M., You, Q., & Jiang, Z. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101266 · Cited by 157
Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction
Hancock, R., Bertrand, H. C., Tsujita, T., Naz, S., El-Bakry, A., Laoruchupong, J., Hayes, J. D., & Wells, G. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.486 · Cited by 151
Nrf2 activation through the inhibition of Keap1–Nrf2 protein–protein interaction
Lee, S., & Hu, L. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02539-y · Cited by 150
Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease
Kerr, F., Sofola-Adesakin, O., Ivanov, D. K., Gatliff, J., Perez‐Nievas, B. G., Bertrand, H. C., Martinez, P., Callard, R., Snoeren, I., Cochemé, H. M., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006593 · Cited by 147
The PTEN/NRF2 Axis Promotes Human Carcinogenesis
Rojo, A. I., Rada, P., Mendiola, M., Ortega-Molina, A., Wojdyła, K., Rogowska-Wrzesińska, A., Hardisson, D., Serrano, M., & Cuadrado, A. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5843 · Cited by 142
Self-citationShimozono, R., Asaoka, Y., Yoshizawa, Y., Aoki, T., Noda, H., Yamada, M., Kaino, M., & Mochizuki, H. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084269 · Cited by 134
Zhang, Y.-B., Yan, T., Sun, D., Xie, C., Wang, T., Liu, X., Wang, J., Wang, Q., Luo, Y., Wang, P., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.12.012 · Cited by 126
Bertrand, H. C., Schaap, M., Baird, L., Georgakopoulos, N., Fowkes, A., Thiollier, C., Kaatchi, H., Dinkova‐Kostova, A. T., & Wells, G. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00602 · Cited by 125
Owens, A. E., Iannuzzelli, J. A., Gu, Y., & Fasan, R. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b00927 · Cited by 120
Lu, M., Ji, J., Jiang, Y.-L., Chen, Z., Yuan, Z., You, Q., & Jiang, Z. (2016) · Scientific Reports · doi:10.1038/srep26585 · Cited by 114
Pallesen, J. S., Tran, K. T., & Bach, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00358 · Cited by 114
Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction
Steel, R., Cowan, J., Payerne, E., O'Connell, M. A., & Searcey, M. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300041g · Cited by 113
Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators
Jain, A. D., Potteti, H. R., Richardson, B. G., Kingsley, L. J., Luciano, J. P., Ryuzoji, A. F., Lee, H., Krunić, A., Mesecar, A. D., Reddy, S. P., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.049 · Cited by 111
Tran, K. T., Pallesen, J. S., Solbak, S. M. Ø., Narayanan, D., Baig, A., Zang, J., Aguayo‐Orozco, A., Carmona, R. M., Garcia, A. D., & Bach, A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00723 · Cited by 108
Kim, S., Viswanath, A. N. I., Park, J., Lee, H. E., Park, A. Y., Choi, J., Kim, H. J., Londhe, A. M., Jang, B. K., Lee, J., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107989 · Cited by 108
Inoyama, D., Chen, Y., Huang, X., Beamer, L. J., Kong, A. T., & Hu, L. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111430124 · Cited by 105
Winkel, A. F., Engel, C. K., Margerie, D., Kannt, A., Szillat, H., Glombik, H., Kallus, C., Ruf, S. G., Güssregen, S., Riedel, J., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.678136 · Cited by 104
Heightman, T. D., Callahan, J. F., Chiarparin, E., Coyle, J. E., Griffiths-Jones, C., Lakdawala, A. S., McMenamin, R. L., Mortenson, P. N., Norton, D., Peakman, T. M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00279 · Cited by 103
Chaperone‐mediated autophagy degrades Keap1 and promotes Nrf2‐mediated antioxidative response
Zhu, L., He, S., Huang, L. H., Ren, D., Nie, T., Tao, K. X., Li, X., Lu, F., Mao, Z., & Yang, Q. (2022) · Aging Cell · doi:10.1111/acel.13616 · Cited by 95
Jiang, Z., Xu, L., Lu, M., Chen, Z., Yuan, Z., Xu, X., Guo, X., Zhang, X., Sun, H.-P., & You, Q. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00185 · Cited by 94
Hancock, R., Schaap, M., Pfister, H., & Wells, G. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40249e · Cited by 91
Tu, J., Zhang, X., Zhu, Y., Dai, Y., Li, N., Yang, F., Zhang, Q., Brann, D. W., & Wang, R. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1304-15.2015 · Cited by 90
Gaćeša, R., Lawrence, K. P., Georgakopoulos, N., Yabe, K., Dunlap, W. C., Barlow, D. J., Wells, G., Young, A. R., & Long, P. F. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.020 · Cited by 90
Chen, Y., Inoyama, D., Kong, A. T., Beamer, L. J., & Hu, L. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01240.x · Cited by 87
Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors
Mou, Y., Wen, S., Li, Y., Gao, X., Zhang, X., & Jiang, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112532 · Cited by 86
Lu, M., Jiao, Q., Liu, T., Tan, S.-J., Zhou, H.-S., You, Q., & Jiang, Z. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.052 · Cited by 83
Li, L., Liu, J., Nie, S., Ding, L., Wang, L., Liu, J., Liu, W., & Zhang, T. (2017) · RSC Advances · doi:10.1039/c7ra04352j · Cited by 82
Tsakiri, E. N., Gumeni, S., Iliaki, K. K., Benaki, D. C., Vougas, K. N., Sykiotis, G. P., Gorgoulis, V. G., Mikros, E., Scorrano, L., & Trougakos, I. P. (2018) · Aging Cell · doi:10.1111/acel.12845 · Cited by 74
Sun, Y., Huang, J., Chen, Y., Shang, H., Zhang, W., Yu, J., He, L., Xing, C., & Zhuang, C. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104172 · Cited by 73
Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists
Bewley, M. A., Budd, R. C., Ryan, E. M., Cole, J., Collini, P., Marshall, J. L., Kolsum, U., Beech, G., Emes, R. D., Tcherniaeva, I., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201705-0903oc · Cited by 73
Zhang, Y., Shi, Z., Zhou, Y., Xiao, Q., Wang, H., & Peng, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01865 · Cited by 67
Pallesen, J. S., Narayanan, D., Tran, K. T., Solbak, S. M. Ø., Marseglia, G., Sørensen, L. M. E., Høj, L. J., Munafò, F., Carmona, R. M., Garcia, A. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02094 · Cited by 66
Zheng, S., Laxmi, Y. R. S., David, E., Dinkova‐Kostova, A. T., Shiavoni, K. H., Ren, Y., Zheng, Y., Isaac, T., Bumeister, R., Ojima, I., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003922 · Cited by 65
The status of Nrf2-based therapeutics: current perspectives and future prospects
Gazaryan, I. G., & Thomas, B. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.194706 · Cited by 64
Fucoxanthin Prevents 6‐OHDA‐Induced Neurotoxicity by Targeting Keap1
Wu, W., Han, H., Liu, J., Tang, M., Wu, X., Cao, X., Zhao, T., Lu, Y., Niu, T., Chen, J., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6688708 · Cited by 63
Jiang, C., Zhuang, C., Zhu, K., Zhang, J., Muehlmann, L. A., Longo, J. P. F., Azevedo, R. B., Zhang, W., Meng, N., & Zhang, H. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1461856 · Cited by 60
Sun, H.-P., Jiang, Z., Zhang, M.-Y., Lu, M., Yang, T., Pan, Y., Huang, H., Zhang, X., & You, Q. (2013) · MedChemComm · doi:10.1039/c3md00240c · Cited by 59
Richardson, B. G., Jain, A. D., Potteti, H. R., Lazzara, P. R., David, B. P., Tamatam, C. R., Choma, E., Skowron, K. J., Dye, K., Siddiqui, Z., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01133 · Cited by 57
Lazzara, P. R., David, B. P., Ankireddy, A., Richardson, B. G., Dye, K., Ratia, K. M., Reddy, S. P., & Moore, T. W. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01074 · Cited by 56
Binding thermodynamics and kinetics guided optimization of potent Keap1–Nrf2 peptide inhibitors
Lu, M.-C., Chen, Z.-Y., Wang, Y.-L., Jiang, Y.-L., Yuan, Z.-W., You, Q.-D., & Jiang, Z.-Y. (2015) · RSC Advances · doi:10.1039/c5ra16262a · Cited by 55 · cited 1×
“Modification of peptide p56 by Lu et al.(71) by incorporation of an N‐terminal Leu and C‐terminal aromatic residues Phe or Tyr led to peptides p87 and p88, which exhibited an improvement in its inhibitory potency (IC50 (FP) = 42.”
BackgroundInduction of Heme Oxygenase I (HMOX1) by HPP-4382: A Novel Modulator of Bach1 Activity
Attucks, O. C., Jasmer, K. J., Hannink, M., Kassis, J. N., Zhong, Z., Gupta, S., Victory, S. F., Güzel, M., Rao, P. D., Andrews, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101044 · Cited by 55
Reversible Keap1 inhibitors are preferential pharmacological tools to modulate cellular mitophagy
Georgakopoulos, N., Frison, M., Álvarez, M. S., Bertrand, H. C., Wells, G., & Campanella, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-07679-7 · Cited by 54
Leung, C., Zhang, J.-T., Yang, G., Liu, H., Han, Q., & Ma, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184445 · Cited by 54
Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators
Ma, B., Lucas, B. S., Capacci, A. G., Lin, E. Y.-S., Jones, J. H., Dechantsreiter, M. A., Enyedy, I. J., Marcotte, D. J., Xiao, G., Li, B., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126852 · Cited by 51
Zhou, H.-S., Hu, L.-B., Zhang, H., Shan, W.-X., Wang, Y., Li, X., Liu, T., Zhao, J., You, Q., & Jiang, Z. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01116 · Cited by 51
Yasuda, D., Nakajima, M., Yuasa, A., Obata, R., Takahashi, K., Ohe, T., Ichimura, Y., Komatsu, M., Yamamoto, M. P., Imamura, R. M., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.083 · Cited by 50
Mining Natural Products for Macrocycles to Drug Difficult Targets
Begnini, F., Poongavanam, V., Over, B., Castaldo, M., Geschwindner, S., Johansson, P., Tyagi, M., Tyrchan, C., Wissler, L., Sjö, P., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01569 · Cited by 50
Hui, Q., Karlstetter, M., Xu, Z., Yang, J., Zhou, L., Eilken, H. M., Terjung, C., Cho, H., Gong, J., Lai, M. J., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.10.414 · Cited by 49
Li, G., Liu, H., Feng, R., Kang, T., Wang, W., Ko, C.-N., Wong, C., Ye, M., Ma, D., Wan, J., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102129 · Cited by 44
Hyperactivation of Nrf2 leads to hypoplasia of bone in vivo
Yoshida, E., Suzuki, T., Morita, M., Taguchi, K., Tsuchida, K., Motohashi, H., Doita, M., & Yamamoto, M. P. (2018) · Genes to Cells · doi:10.1111/gtc.12579 · Cited by 42
Lu, M., Zhang, X., Wu, F., Tan, S.-J., Zhao, J., You, Q., & Jiang, Z. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00818 · Cited by 41
Lu, M., Zhang, X., Zhao, J., You, Q., & Jiang, Z. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101565 · Cited by 41
Georgakopoulos, N., Talapatra, S. K., Gatliff, J., Kozielski, F., & Wells, G. (2018) · ChemBioChem · doi:10.1002/cbic.201800170 · Cited by 40
Development of a Cell-Permeable Cyclic Peptidyl Inhibitor against the Keap1–Nrf2 Interaction
Salim, H., Song, J., Sahni, A., & Pei, D. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b02367 · Cited by 40
Lu, M., Shao, H.-L., Liu, T., You, Q., & Jiang, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112734 · Cited by 40
Meng, N., Tang, H., Zhang, H., Jiang, C., Su, L., Min, X., Zhang, W., Zhang, H., Miao, Z., Zhang, W., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.02.010 · Cited by 37
Satoh, M., Saburi, H., Tanaka, T. U., Matsuura, Y., Naitow, H., Shimozono, R., Yamamoto, N., Inoue, H., Nakamura, N., Yoshizawa, Y., et al. (2015) · FEBS Open Bio · doi:10.1016/j.fob.2015.06.011 · Cited by 36
NRF2 in neurodegenerative diseases
Cuadrado, A. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.09.004 · Cited by 36
Self-citationYasuda, D., Ohe, T., Takahashi, K., Imamura, R. M., Kojima, H., Okabe, T., Ichimura, Y., Komatsu, M., Yamamoto, M. P., Nagano, T., et al. (2020) · Free Radical Research · doi:10.1080/10715762.2020.1732955 · Cited by 36
Polar Recognition Group Study of Keap1-Nrf2 Protein–Protein Interaction Inhibitors
Lu, M., Tan, S.-J., Ji, J., Chen, Z., Yuan, Z., You, Q., & Jiang, Z. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00407 · Cited by 35
A novel strategy to activate cytoprotective genes in the injured brain
Zhao, J., Redell, J. B., Moore, A. N., & Dash, P. K. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.046 · Cited by 33
Yasuda, D., Yuasa, A., Obata, R., Nakajima, M., Takahashi, K., Ohe, T., Ichimura, Y., Komatsu, M., Yamamoto, M. P., Imamura, R. M., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.008 · Cited by 33
Abed, D. A., Lee, S., & Hu, L. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115343 · Cited by 33
Ontoria, J. M., Biancofiore, I., Fezzardi, P., Ferrigno, F., Torrente, E., Colarusso, S., Bianchi, E., Andreini, M., Patsilinakos, A., Kempf, G., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00594 · Cited by 32
Casares, L., Moreno, R., Ali, K. X., Higgins, M., Naidu, S. D., Neill, G., Cassin, L., Kiib, A. E., Svenningsen, E. B., Minassi, A., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102291 · Cited by 31
Noel, S., Arend, L. J., Bandapalle, S., Reddy, S. P., & Rabb, H. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0310-y · Cited by 30
Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interaction
Steel, R., O'Connell, M. A., & Searcey, M. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.03.003 · Cited by 29
Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction
Colarusso, S., Simone, D. D., Frattarelli, T., Andreini, M., Cerretani, M., Missineo, A., Moretti, D., Tambone, S., Kempf, G., Augustin, M. A., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115738 · Cited by 29
Synthesis and Evaluation of Noncovalent Naphthalene-Based KEAP1-NRF2 Inhibitors
Lazzara, P. R., Jain, A. D., Maldonado, A. C., Richardson, B. G., Skowron, K. J., David, B. P., Siddiqui, Z., Ratia, K. M., & Moore, T. W. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00631 · Cited by 28
Activation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor
Wen, X., Thorne, G., Hu, L., Joy, M. S., & Aleksunes, L. M. (2015) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21693 · Cited by 27
Wang, L., Chen, X., Li, X., Liu, D., Wang, X., Chang, X., & Guo, Y. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.03.039 · Cited by 26
Shimizu, Y., Yonezawa, T., Sakamoto, J., Furuya, T., Osawa, M., & Ikeda, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-86616-1 · Cited by 23
Chen, K., Huang, L., & Shen, B. (2018) · Biophysical Chemistry · doi:10.1016/j.bpc.2018.11.002 · Cited by 19
Lu, M., Zhou, H.-S., You, Q., & Jiang, Z. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00775 · Cited by 18
Sogabe, S., Sakamoto, K., Kamada, Y., Kadotani, A., Fukuda, Y., & Sakamoto, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.038 · Cited by 15
Cited by
Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
Self-citation
Metadata
- Authors
- Crisman, E., Duarte, P., Dauden, E., Cuadrado, A., Rodríguez‐Franco, M. I., López, M. G., & León, R.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2022-09-10
- Volume
- 43
- Issue
- 1
- Pages
- 237-287
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W4295095218
- Cited by
- 257
- References
- 141
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.